Literature DB >> 15678034

Lobar and sublobar resection with and without brachytherapy for small stage IA non-small cell lung cancer.

Hiran C Fernando1, Ricardo S Santos, John R Benfield, Frederic W Grannis, Robert J Keenan, James D Luketich, John M Close, Rodney J Landreneau.   

Abstract

OBJECTIVE: Computed tomographic screening is detecting ever smaller peripheral non-small cell lung cancers. These smaller cancers are amenable to sublobar resection, but sublobar resection is not currently the treatment of choice. This study compared sublobar resection with lobar resection for stage IA non-small cell lung cancers to assess whether sublobar resection is appropriate treatment for certain lesions. The use of adjuvant brachytherapy was also evaluated.
METHODS: A retrospective multicenter study of 291 patients with T1 N0 disease was done. Outcomes after sublobar resection (n = 124) were compared with those after lobar resection (n = 167). Brachytherapy was used in conjunction with 60 (48%) sublobar resection operations. Analysis based on tumor diameter was performed.
RESULTS: There were 137 cancers smaller than 2 cm and 154 cancers ranging from 2 to 3 cm. Patients undergoing sublobar resection were older (68.4 vs 66.1 years, P = .018) with poorer pulmonary function (forced expiratory volume in 1 second of 53.1% vs 78.2%, P = .001). Mean follow-up was 34.5 months. Brachytherapy decreased local recurrence rate significantly among patients undergoing sublobar resection, from 11 (17.2%) to 2 (3.3%). For tumors smaller than 2 cm, there was no difference in survival between sublobar resection and lobar resection groups. For the larger tumors (2-3 cm), median survival was significantly better in the lobar resection group, at 70 versus 44.7 months ( P = .003).
CONCLUSION: Intraoperative brachytherapy may reduce the local recurrence that is usually reported with sublobar resection. Our experience supports the further investigation of the use of sublobar resection with brachytherapy for peripheral stage IA non-small cell lung cancers smaller than 2 cm.

Entities:  

Mesh:

Year:  2005        PMID: 15678034     DOI: 10.1016/j.jtcvs.2004.09.025

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  23 in total

1.  Clinical implications of the margin cytology findings and margin/tumor size ratio in patients who underwent pulmonary excision for peripheral non-small cell lung cancer.

Authors:  Noriyoshi Sawabata; Hajime Maeda; Akihide Matsumura; Mitsunori Ohta; Meinoshin Okumura
Journal:  Surg Today       Date:  2011-11-10       Impact factor: 2.549

Review 2.  Radical sublobar resection for lung cancer.

Authors:  Morihito Okada
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-04-10

3.  Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller.

Authors:  Jun-ichi Nitadori; Adam J Bograd; Kyuichi Kadota; Camelia S Sima; Nabil P Rizk; Eduardo A Morales; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  J Natl Cancer Inst       Date:  2013-08-07       Impact factor: 13.506

4.  Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer.

Authors:  Hiran C Fernando; Rodney J Landreneau; Sumithra J Mandrekar; Francis C Nichols; Shauna L Hillman; Dwight E Heron; Bryan F Meyers; Thomas A DiPetrillo; David R Jones; Sandra L Starnes; Angelina D Tan; Benedict D T Daly; Joe B Putnam
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

5.  Recovery of lung function after segmentectomy versus lobectomy for early-stage lung cancer.

Authors:  Tawee Tanvetyanon; Robert J Keenan
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

6.  The impact of adjuvant brachytherapy with sublobar resection on pulmonary function and dyspnea in high-risk patients with operable disease: preliminary results from the American College of Surgeons Oncology Group Z4032 trial.

Authors:  Hiran C Fernando; Rodney J Landreneau; Sumithra J Mandrekar; Shauna L Hillman; Francis C Nichols; Bryan Meyers; Thomas A DiPetrillo; Dwight Heron; David R Jones; Benedict D T Daly; Sandra L Starnes; Jeffrey E Hatter; Joe B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  2011-07-02       Impact factor: 5.209

Review 7.  Emerging treatment options in the management of non-small cell lung cancer.

Authors:  Pier Luigi Filosso; Alberto Sandri; Alberto Oliaro; Andrea Riccardo Filippi; Maria Carla Cassinis; Umberto Ricardi; Paolo Olivo Lausi; Sofia Asioli; Enrico Ruffini
Journal:  Lung Cancer (Auckl)       Date:  2011-06-08

Review 8.  Locoregional recurrence after pulmonary sublobar resection of non-small cell lung cancer: can it be reduced by considering cancer cells at the surgical margin?

Authors:  Noriyoshi Sawabata
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-09-29

Review 9.  Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer?

Authors:  Sarah Mahmood; Haris Bilal; Corinne Faivre-Finn; Rajesh Shah
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-07-30

10.  What is the role of wedge resection for T1a lung cancer?

Authors:  Sebron Harrison; Brendon Stiles; Nasser Altorki
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.